FDA approves valve treated to prevent calcification

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The FDA approved a bioprosthetic heart valve that is treated to improve durability.

The Italian company Sorin Group announced that it received FDA approval for its Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment. The treatment extracts phospholipids from pericardial tissue. Phospholipids have been linked to the calcification process of bioprotheses, which affects durability. In animal models, the treatment process reduced calcium uptake compared with a control.

Mitroflow with Phospholipid Reduction Treatment received CE mark on July 28, 2011.

Candace Stuart, Contributor

Related Content

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
Bringing state-of-the-art healthcare to Florida heart patients
Cardiologists make case against routine interventions for asymptomatic severe AS
First comprehensive T-TEER resource examines best practices for tricuspid valve repair
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.